Company: TAK
Filing Date: 2025-05-08
Form Type: 6-K
Source: 0001395064-25-000048
Chunk: 13

Company: TAKEDA PHARMACEUTICAL CO LTD
Filing Date: 2025-05-08
Form: 6-K
Chunk 13
---
 31, 2024 resulting from the reversal of the income taxes payable in excess of the settlement with Irish Revenue Commissioners with respect to a tax assessment related to the treatment of an acquisition break fee Shire received from AbbVie in 2014 and an increase in tax expenses due to the reassessment of recoverability of deferred tax assets as well as higher pretax earnings during the fiscal year ended March 31, 2025.

#### Net Profit for the Year
As a result of the above factors, Net Profit for the Year was JPY 108.1 billion ( JPY -36.1 billion and -25.0% AER , -33.1% CER ) and Net Profit for the Year attributable to owners of the Company was JPY 107.9 billion ( JPY -36.1 billion and -25.1% AER, -33.2% CER).

<div align='center'>6</div>

Takeda Pharmaceutical Company Limited (4502)

Earnings Report ( Kessan Tanshin ) for the Fiscal Year

Ended March 31, 2025 (Consolidated)

(iii) Results of Core Financial Measures (April 1, 2024 to March 31, 2025)

Definition and Explanation of Core Financial Measures and Constant Exchange Rate Change

In addition to the financial statements in accordance with IFRS, Takeda uses the concept of Core Financial Measures for measuring financial performance. These measures are not defined by International Financial Reporting Standards (IFRS). See “Definition and Explanation of Non-IFRS Measures and U.S. Dollar Convenience Translations” in the Financial Appendix for additional information.

| 2024                                                               |     | For the fiscal year ended 
 March 31,                 |     | 2025 |         |     | Amount of Change |     |         |     | AER      
 % Change |     |       |     | % Change |     |      |   | CER |     |      | Billion JPY or percentage |
|:-------------------------------------------------------------------|:----|:--------------------------|:----|:-----|--------:|:----|:-----------------|:----|--------:|:----|:---------|:----|------:|:----|:---------|:----|-----:|:--|:----|:----|-----:|:--------------------------|
| Core revenue                                                       |     |                           |     |      | 4,263.8 |     |